Palabras clave
Eficacia
Obesidad
Seguridad
Cómo citar
Copyright © | Todos los derechos reservados.
La revista posee los derechos de autor exclusivos para la publicación de este artículo en los términos de la ley brasileña 9610/98.
Reproducción parcial
El uso de partes de los textos, figuras y cuestionario del artículo es libre, siendo obligatoria la citación de los autores y revista.
Reproducción total
Está expresamente prohibido y debe ser autorizado por la revista.
Resumen
Objetivo: Analizar la eficacia y la seguridad del uso de análogos de GLP-1 como farmacoterapia para el tratamiento de la obesidad a partir de la literatura científica. Métodos: Se trata de una revisión integrativa de la literatura, con artículos de texto completo y acceso gratuito, en portugués o inglés, sin un marco temporal, con búsquedas realizadas en las bases de datos Scientific Eletronic Library (SCIELO), PubMed y BVS mediante descriptores en ciencias de la salud (DeCS) en portugués e inglès (MeSH) combinados con operadores booleanos. Se utilizó como pregunta orientadora: ¿Son eficaces y seguros los análogos de GLP-1 en eltratamiento de la obesidad? Resultados: Después de una selección rigurosa, 19 artículos se ajustaron a los criterios de inclusión y exclusión, respondiendo a la pregunta orientadora y enriqueciendo la revisión. Consideraciones finales: Los análogos de GLP-1 son seguros y eficaces para el tratamiento de la obesidad, teniendo un efecto superior a otros métodos y pudiendo ser potenciados a través de la asociación con actividad física regular, dieta hipocalóricay terapia conductual intensiva. Además, presentan efectos adversos mínimos y tolerables con menores riesgos de complicaciones.
Referencias
ASTRUP A, et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP1 analog, liraglutide, Int J Obes (Lond), 2012 Jun; 36(6): 843-54.
BARBOZA JJ, et al. Efficacy of Liraglutide in Non-Diabetic Obese Adults: A Systematic Review and Meta- Analysis of Randomized Controlled Trials, J Clin Med, 2022 May 25; 11(11): 2998.
BROWN EMILY, et al. Newer GLP-1 receptor agonists and obesity- diabetes, Peptides, 2018; 100: 61-67.
DENG Y, et al. Effect of semaglutide and liraglutide in individuals with obesity or overweight without diabetes: a systematic review, Ther Adv Chronic Dis., 2022 Jul 4; 13: 20406223221108064.
FDA (2021). FDA Approves New Drug Treatment for Chronic Weight Management, First Since 2014.
FILIPPATOS, et al. Adverse effects of GLP-1 receptor agonists, The review of diabetic studies: RDS, 2014; 11 (3): 202.
FUJIOKA K. Segurança e tolerabilidade de medicamentos aprovados para controle de peso crônico, Obesidade (Silver Spring), 2015; 23(1): 7-11.
GAO X, et al. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials, Front Pharmacol, 2022 Sep 14;13:935823
GUO X, et al. The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis, Horm Metab Res., 2022 Jul; 54(7): 458-471.
HAINER V. Visão geral de novos medicamentos antiobesidade, Opinião de especialista em farmacoterapia, 2014; 15 (14): 1975–1978.
KNUDSE N, et al. The discovery and development of liraglutide and semaglutide, Frontiers in endocrinology, 2019; 10: 155.
KONWAR M, et al. Efficacy and Safety of Liraglutide 3.0 mg in Patients with Overweight and Obese with or without Diabetes: A Systematic Review and Meta-Analysis, Int J Clin Pract, 2022 Jul 19; 2022:1 201977.
LADENHEIM, et al. Liraglutide and obesity: a review of the data so far, Drug design, development and therapy, 2015; 1867-1875.
LE ROUX C, et al. Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis, Obes Facts, 2017; 10(6): 531-544.
LEAN MEJ, et al. Tolerability of nausea and vomiting and associations with weight loss in a randomized trial of liraglutide in obese, non-diabetic adults, International journal of obesity, 2014; 38(5): 689-697
LUNDGREN, et al. Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures, Cardiovascular Diabetology, 2019; 18 (1): 1-9.
MANCINI, M., et al. Tratado de Obesidade, Itapevi: AC Farmacêutica, 2010; 253-264.
MOIZ A, et al. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials, Am J Cardiol, 2024 Jul 1; 222:121-130.
MONAMI M, et al. Effects of glucagon-like peptide-1 receptor agonists on body weight: a meta-analysis, Exp Diabetes Res., 2012; 2012: 672658.
OCA, et al. Obesity and GLP-1, Minerva endocrinology, 2021; 46 (2): 168-176.
O'NEIL PATRICK M, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose- ranging, phase 2 trial, The Lancet, 2018; 392 (10148): 637-649.
OMS. Organização Mundial da Saúde. Global Burden Of Disease, 2018.
PI-SUNYER X, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management, New England Journal of Medicine, 2015; 373 (1): 11-22.
SMITH I, et al. Semaglutide 2.4 Mg for the Management of Overweight and Obesity: Systematic Literature Review and Meta-Analysis, Diabetes Metab Syndr Obes., 2022 Dec 17; 15: 3961-3987
TAN HC, et al. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis, J ASEAN Fed Endocr Soc., 2022; 37(2): 65-72.
TRONIERI JS, et al. Effects of dietary self-monitoring, physical activity, liraglutide 3.0 mg, and placebo on weight loss in the SCALE IBT trial, Obesity Facts, 2020; 13(6): 572-583.
WADDEN TA, et al. Intensive behavioral therapy for obesity combined with liraglutide 3.0 mg: a randomized controlled trial, Obesity, 2019; 27(1): 75-86.
WILDING JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension, Diabetes Obes Metab, 2022 Aug; 24(8): 1553-1564.
XIE Z, et al. Efficacy and Safety of Liraglutide and Semaglutide on Weight Loss in People with Obesity or Overweight: A Systematic Review, Clin Epidemiol, 2022 Dec 6; 14: 1463-1476.